Morgan Hubeli
Family · Charlotte, NCNPI 1043885692
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,590 of the $15,400 with a category attached, or 68.8%. 33 manufacturers reported payments, led by Aytu Biopharma, Inc. at 32.2% of the total. 2025 is the largest year on record at $8,300, more than ten times the $390 reported in 2021. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 536 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aytu Biopharma, Inc.$5K
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- CSL Behring$714
- Sanofi$553
- plus $4K from 27 others
What the payments were for
- Consulting fees$1471%
- Speaking & faculty fees$4,45029%
- Food & beverage$10,59069%
- Education$2141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aytu Biopharma, Inc. | 40 | $4,961 |
| AstraZeneca | 81 | $2,007 |
| GSK | 112 | $1,368 |
| Regeneron Healthcare Solutions, Inc. | 49 | $1,300 |
| CSL Behring | 26 | $714 |
| Sanofi | 16 | $553 |
| ARS Pharmaceuticals Operations, Inc. | 24 | $538 |
| Grifols USA, LLC | 24 | $471 |
| Amgen | 22 | $430 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $380 |
| Novartis | 26 | $349 |
| Kaleo, Inc. | 12 | $251 |
| Octapharma USA, Inc. | 12 | $248 |
| AbbVie | 10 | $230 |
| Incyte Corporation | 6 | $217 |
| Organon | 6 | $189 |
| Optinose US, Inc. | 10 | $183 |
| Pharming Healthcare, Inc. | 4 | $173 |
| Pfizer | 11 | $163 |
| ADMA Biomanufacturing LLC | 6 | $147 |
| Hikma Pharmaceuticals USA | 5 | $89 |
| Ionis Pharmaceuticals, Inc. | 3 | $75 |
| Genentech USA, Inc. | 3 | $70 |
| Biocryst US Sales Co., LLC | 2 | $63 |
| Azurity Pharmaceuticals, Inc. | 2 | $41 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Siemens Medical Solutions USA, Inc. | 1 | $30 |
| Greer Laboratories, Inc. | 1 | $28 |
| Phadia US Inc. | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $22 |
| Invivyd Inc | 1 | $21 |
| GC Biopharma USA, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,400 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $35,595 |
| Arnuity ElliptaFluticasone Furoate | 28 | $6,119 |
| Epinephrine | 27 | $4,948 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,634 |
| Azelastine Hcl | 39 | $1,496 |
| Ipratropium Bromide | 14 | $657 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $550 |
| Fluticasone Propionate | 29 | $351 |
| Montelukast Sodium | 22 | $123 |
| Famotidine | 12 | $121 |
| Levocetirizine Dihydrochloride | 29 | $90 |
| Prednisone | 15 | $19 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta | $1,368 | $41,71473 claims |
| Hikma Pharmaceuticals USAEpinephrine | $89 | $4,94827 claims |
| AstraZenecaSymbicort | $2,007 | $3,63413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Charlotte
- Debra ScottCharlotte$129K
- Lasherri LeathersCharlotte$89K
- Catherine ShahCharlotte$72K
- Jason HardinCharlotte$37K
- Laura ListonCharlotte$33K
- Marie KristensenCharlotte$30K
- Hadley DebergCharlotte$16K
- Trisha WootenCharlotte$15K
- Samantha GriffinCharlotte$13K
- Leslie ByrneFayetteville$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.